<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856101</url>
  </required_header>
  <id_info>
    <org_study_id>UCL-ONCO2012-01</org_study_id>
    <secondary_id>2012-004123-20</secondary_id>
    <nct_id>NCT01856101</nct_id>
  </id_info>
  <brief_title>Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy</brief_title>
  <acronym>BEZ235</acronym>
  <official_title>A Single Arm, Multicenter, Phase II Study of BEZ235 as Monotherapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) After Failure of Platinum Based Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mTOR (mammalian Target of Rapamycin) protein is the center of the mTOR pathway that plays
      an important role in cell growth, proliferation, survival and angiogenesis through sensing
      and integrating energetic signals from cellular environment. The mTOR protein is composed of
      two complex, mTOR complex 1 (mTOR C1) and mTOR complex 2 (mTOR C2).

      In regards of mTOR pathway dysregulations observed in TCC development, there is a rational to
      test BEZ23 in advanced TCC. BEZ235 is a pan-class I PI3K inhibitor that, in addition, binds
      to the catalytic site of mTOR, inhibiting mTOR C1 and mTOR C2.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Novartis decided to stop the marketing of BEZ235
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the efficacy of BEZ235 in patients with palliative TCC</measure>
    <time_frame>at 16 weeks (radiological evaluation every 8 weeks)</time_frame>
    <description>o Control disease rate at 16 weeks, including complete responses, partial responses and stable diseases according to RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the safety profile of BEZ235 in patients with advanced TCC</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 16 weeks</time_frame>
    <description>The patient will have an appointment with the investigator on day 15 of cycle 1 and every day 1 of each cycle.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Carcinoma Transitional Cell</condition>
  <arm_group>
    <arm_group_label>BEZ235, powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: patients without PI3K pathway activation; no loss of PTEN and no activating PIK3CA mutation.
Group 2: patients with PI3K pathway activation as defined by PIK3CA mutation and/or PTEN loss</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEZ235</intervention_name>
    <description>The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid</description>
    <arm_group_label>BEZ235, powder</arm_group_label>
    <other_name>BEZ235 is a potent dual pan class I PI3K and mTOR inhibitor.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically- or cytologically-confirmed locally advanced or
             metastatic TCC not amenable to curative surgery or radiation.

          2. Documented disease progression (according RECIST 1.1 criteria) after first line
             platinum-based therapy (given in neoadjuvant/adjuvant or palliative setting).

          3. An interval of &gt;4 weeks since last anticancer treatment.

          4. Archival paraffin-embedded tumor tissue (block or at least 20 unstained slides) of the
             primary tumor and/or metastases. The most recent archival tissue is mandatory.
             Recidive of the disease should lead to perform if possible novel biopsies, as major
             oncogenic differences are found between primary tumor and secondary lesions.

          5. At least one measurable lesion by MRI or CT-scan

          6. ECOG performance status 0-1, in stable medical condition

          7. Patients must have adequate organ function: Hemoglobin ≥ 9 g/100 ml, neutrophils ≥
             1,000/mm3, platelets ≥ 100,000/mm, INR ≤ 1.5, total serum bilirubin ≤ 1.5 x ULN,
             alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN (or &lt;5.0
             x ULN if hepatic metastases are present), creatinine £1.5 x ULN, fasting plasma
             glucose &lt;140mg/dl, HbA1c &lt; 8%.

          8. Patients must be over 18 years old and able to give written informed consent.

          9. Signed informed consent prior to beginning protocol specific procedure

        Exclusion Criteria:

          1. Non- TCC bladder cancer

          2. More than 2 prior chemotherapy regimens given for palliation.

          3. Concurrent malignancy or previous malignancy in the last 3 years prior to start the
             study treatment (with the exception of a history of adequately treated cervical
             carcinoma in situ or non-melanoma skin cancer)

          4. Patient with active uncontrolled or symptomatic central nervous system (CNS
             metastases).

          5. Significant active cardiac disease including uncontrolled high blood pressure,
             unstable angina, congestive heart failure, myocardial infarction within the previous 6
             months, or serious cardiac arrhythmias.

          6. Other uncontrolled medical condition (active infections requiring antibiotics,
             bleeding disorders, uncontrolled diabetes …)

          7. Other concomitant anticancer therapy.

          8. Previous therapy with PI3K and/or mTOR inhibitors (sirolimus, temsirolimus,
             everolimus)

          9. Concomitant drugs such as coumarin and warfarin, and drugs known to induce torsade de
             pointe, drugs known to be moderate or strong inhibitors or inducers of CYP3A4

         10. Pregnancy or risk of pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pascal Machiels, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre du Cancer, Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Saint-Pierre à Ottignies</name>
      <address>
        <city>Ottignies</city>
        <state>Brabant Wallon</state>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epicura- RHMS Baudour</name>
      <address>
        <city>Baudour</city>
        <state>Hainaut</state>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Jolimont</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <state>Hainaut</state>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Wallonie Picarde</name>
      <address>
        <city>Tournai</city>
        <state>Hainaut</state>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège site du Sart Tilman</name>
      <address>
        <city>Liège 1</city>
        <state>Liège</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Sud Luxembourg</name>
      <address>
        <city>Arlon</city>
        <state>Luxembourg</state>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique et Maternité Ste Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <state>Grand-Duché de Luxembourg</state>
        <zip>1210</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TCC</keyword>
  <keyword>Failure of platinum based chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dactolisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

